Cardil

Diltiazem HCl

Angina pectoris, Prinzmetal's angina, HTN.

1-1½ tab once or bd.

May be taken with or without food: Swallow whole, do not chew/crush.

Hypersensitivity. Cardiogenic shock, decompensated cardiac insufficiency, sick sinus syndrome or evidence of 2nd- or 3rd-degree AV block (w/o pacemaker), hypotension, severe bradycardia (<40 bpm), Wolff-Parkinson-White syndrome, acute complicated MI, left ventricular failure w/ pulmonary congestion, digitalis-intoxication. Concomitant use of dantrolene infusion. Pregnancy or lactation.

Reduced left ventricular function, bradycardia or 1st-degree AV block, aortic stenosis; acute porphyria; mood changes eg, depression; risk of intestinal obstruction. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency, fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency. Concomitant use w/ β-blockers or other drugs impairing cardiac conduction or contractility; anaesth. May affect ability to drive & use machines. Renal or hepatic impairment. Not recommended in women of childbearing potential & during pregnancy. Not to be used during lactation. Elderly.

Headache, dizziness, AV block, palpitations, peripheral oedema, flushing of face, nausea, constipation, dyspepsia, gastric pain, malaise, erythema, pruritus.

Lethal ventricular fibrillation w/ dantrolene infusion. Monitor lithium serum conc. Increased hypotensive effects, faintness w/ nitrate derivatives. Increased circulating theophylline, carbamazepine, cyclosporine levels. Increased antihypertensive effects w/ α-antagonists. Increased risk of bradycardia w/ amiodarone, digoxin. Possibility of rhythm disturbances, SA & AV conduction disturbances, heart failure w/ β-blockers. Additive risk of increased cardiac adverse effects w/ other antiarrhythmic agents. Decreased plasma levels w/ rifampicin, CYP3A4 inducers. Increased plasma conc w/ anti-H₂ agents eg, ranitidine; strong CYP3A4 inhibitors, other CYP3A4 substrates eg, macrolide antibiotics, phenytoin, buspirone, nifedipine, sirolimus, tacrolimus, alfentanil, cisapride, HIV PIs. Increased cardiac depressant effect of halothane, isoflurane. Potential for additive effects w/ other agents affecting cardiac contractility &/or conduction. Potentiated effect w/ other antihypertensive agents. Increased plasma conc of midazolam, triazolam, alprazolam. Inhibition of methylprednisolone metabolism. Increased AUC of some statins eg, simvastatin, lovastatin, atorvastatin.

Calcium Antagonists

C08DB01 - diltiazem ; Belongs to the class of benzothiazepine derivative selective calcium-channel blockers with direct cardiac effects. Used in the treatment of cardiovascular diseases.

B